The goal of the Career Enhancement Program of the Yale SPORE in Lung Cancer is to educate the next generation of investigators committed to translational research in lung cancer. The Career Enhancement Program will provide support of up to $50,000 to promising junior investigators and/or establish investigators who have not previously conducted lung cancer focused research. Proposed pilot projects should be innovative and be focused on a broad spectrum of research, and/or technology development applicable to human lung cancer risk, prevention, diagnosis, prognosis, or treatment.
Award Amounts: Up to $50,000 for one year.
Purpose: To provide support to foster the development of the next generation of lung cancer translational researchers. The aims of the Career Enhancement Program are to support promising early career stage lung cancer investigators and to enhance the careers of established investigators who have newly defined interests in pursing translational research in lung cancer. The purpose is also to generate preliminary data or evidence of collaboration for new NCI grant applications.
Eligibility: Open to investigators at an academic institution who can be described by one of the following categories:
Women and minority investigators are strongly encouraged to apply.
Requirements: If a grant is awarded, the P.I. and mentors must agree to abide by the attached Grant Guidelines (page 4) and to participate in the DRP/CEP Symposium to be held at Yale in May 2025 (tentative date).
Deadlines:
Letters of Intent and applications should be submitted at https://yale.infoready4.com
Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; Director, Yale SPORE in Skin Cancer, Yale Cancer Center; Vice Chair for Collaborative Research, Internal Medicine; Chief, Division of Skin and Kidney Cancer; Associate Cancer Center Director, Education, Training and Faculty Development; Deputy Section Chief, Medical Oncology
Amy and Joseph Perella Professor of Medicine (Medical Oncology); Chief, Experimental Therapeutics; Associate Cancer Center Director, Experimental Therapeutics